Mitch Levine

Nov 15, 2017

OncoCyte said that Mitch Levine has been appointed chief financial officer. Prior to joining OncoCyte, Levine was managing partner of Kirby Cover Capital Advisors, which provides consulting to international life sciences investment funds regarding US-based companies. In 2002 Levine founded Enable Capital Management. Prior to that, he was a founding member of The Shemano Group. He has also worked for Bear Stearns and Lehman Brothers.

More Like This

Oct 16, 2018

Tom Copa

Asuragen has hired Tom Copa as its SVP, commercial operations. Copa will lead the global sales, marketing, and customer solutions teams for the firm's diagnostics products business. Prior to Asuragen, Copa served as VP of licensed technologies at Luminex, as well as spending over 16 years as a senior executive in several roles at the firm. 

Oct 15, 2018

Robert Ford

Abbott announced that Robert Ford has been named president and chief operating officer. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott's largest business.

In addition to his current responsibilities for Medical Devices, Ford will assume responsibility for all of Abbott's operating businesses. He will continue to report to the firm's Chairman and CEO Miles White.

Ford has held various management positions across several of Abbott's businesses, including Diagnostics, Nutrition, and Medical Devices. As head of the firm's Medical Devices business for the past three years, he oversaw the integration of the St. Jude Medical acquisition. He previously led Abbott's Diabetes Care business and the launch of its glucose monitoring system, FreeStyle Libre. 

Oct 12, 2018

David Stark

Parallax Diagnostics has appointed David Stark its president, the company's parent firm Parallax Health Sciences, said. Stark has more than 20 years of experience in healthcare R&D, clinical research, regulatory affairs, and marketing. He was director of development for clinical research organization Spaulding Clinical Research and director of business development, West Coast for MedSource. Before that, he was development director, West Coast for Veristat. 

Oct 12, 2018

Jane Schwebke

Talis Biomedical has appointed Jane Schwebke to its scientific advisory board. Both a professor of medicine in the infectious disease division at the University of Alabama at Birmingham and a consultant to the Jefferson County Department of Health STD clinic, Schwebke previously served as medical director of the Harborview STD Clinic in Seattle and as director for Chicago's STD/HIV Program.

Oct 11, 2018

Jörg Debatin

Jörg Debatin has been appointed chairman of the supervisory board of Hummingbird Diagnostics. Debatin previously served as VP and chief technology officer of GE Healthcare and CEO of Amedes. In addition, he has also served as the medical director and CEO of the University Hospital Hamburg-Eppendorf.

Oct 11, 2018

John Glasspool

VisionGate has appointed John Glasspool as Chief Operating and Strategy Officer and to the firm's board of directors. Glasspool is currently a member of the board of directors of Dalcor. In addition, he is an advisor to MIT Newdigs and leads the FoCUS project, looking at pricing and policy for durable oncology therapies. Glasspool's career includes executive and management responsibilities at pharmaceutical companies, including Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. Glasspool has also served on the board of directors and as president of Vaccines Europe at the Biotechnology Industry Organization.

Oct 10, 2018

Richard Yost

Owlstone Medical appointed Richard Yost to its scientific advisory board. He is a professor and head of analytical chemistry at the University of Florida and has particular expertise in tandem mass spectrometry. Yost is the co-inventor of the triple quadrupole mass spectrometer, Owlstone added. 

Oct 09, 2018

Michel Finance

Michel Finance is leaving his post as CEO of Theradiag, the company announced. No reason was given for his departure. Finance will stay on at Theradiag until Dec. 31. A search for his successor has begun. 

Oct 09, 2018

Susan Evans, Donna Edmonds

ImmunArray announced Susan Evans will become its new CEO, replacing Donna Edmonds, who will become the chair and CEO of ImmunArray's new spinoff called BrainBox Solutions based in Richmond, Virginia.

Evans began her career at Baxter Diagnostics and Dade Behring, where held various positions in R&D including senior vice president. She also held senior R&D postions in Caliper Life Sciences and Life Scan, and was vice president scientific affairs, and vice president/general manager of Beckman Coulter Genomics. 

Edmonds, meanwhile, will remain executive chair of ImmunArray. 

Oct 08, 2018

Stan Lapidus, Howard Heller, Margaret Higham

Atlas Genetics has changed its name to Binx Health and announced several additions to the company, including the appointment of Stan Lapidus as chairman of the board. Lapidus is the founder of Exact Sciences and Helicos BioSciences.

Also, Howard Heller was appointed Binx's chief medical officer while Margaret Higham was named its director of medical affairs. Heller directs infection control and prevention at the Massachusetts Institute of Technology and provides clinical care at Massachusetts General Hospital. Higham is an infectious disease expert and medical director of the Student Health Service at Tufts University.

Oct 04, 2018

David Grenache

The American Association of Clinical Chemistry announced that David Grenache has been elected to serve on the AACC board of directors as president-elect starting in January 2019. He will then serve as the association's president from August 2020 to July 2021, and past president from August 2021 to July 2022. Grenache is the chief scientific officer and medical director of the chemistry, immunology, and esoteric analytic chemistry labs at TriCore Reference Laboratories, and clinical professor of pathology at the University of New Mexico.

Oct 03, 2018

Tom Polen

Tom Polen, who currently serves as president of BD, has been promoted. He will now also serve as BD's Chief Operating Officer. Polen will be responsible for overseeing the firm's three operating segments, its new product development pipeline, and global operations including all manufacturing facilities and supply chain operations. The company has not had a COO since 2016, according to a statement.

Oct 03, 2018

Jürgen Schulze, Alain Baverel

Sysmex Europe announced that Jürgen Schulze, its chairman, long-time president, and CEO, retired at the end of September. He will continue to support Sysmex as a member and vice-chairman of the MedTech Europe Executive Board, the firm said.

Schulze passed the baton to Alain Baverel, who has been transitioning into his role as president and CEO of Sysmex EMEA since April 2018. His role became official Oct. 1.

Baverel joined Sysmex in 2007 as managing director of the newly established affiliate Sysmex France.

Oct 03, 2018

Hayden Jeffreys

Hayden Jeffreys has become group commercial director at Premaitha Health. He joined the company from Cambridge Epigenetix, where he was chief operating officer. Before that, he was interim CEO at ERBA Diagnostics. Jeffreys holds an MSc in management studies from the University of Oxford and a BSc in genetics from Cardiff University.

Oct 02, 2018

Lawrence Culp

Former Danaher President and CEO Lawrence Culp was named the Chairman and CEO of GE on Oct. 1, effective immediately. He replaces John Flannery in the two positions. Culp has been a member of GE's board since April and led Danaher between 2000 and 2014.